Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

4期 已完成 NCT05329194

摘要

To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.

Annualized Asthma Exacerbation Rate (AAER)

Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52) · Adjusted rate (exacerbations per year)

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
• Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
• A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
• A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
• A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
• Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma — ARS Pharmaceuticals, Inc.

全部试验